(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Patients with inadequate health insurance were more likely to receive mastectomy, omit RT following breast-conserving surgery, and receive PMRT. Differences in clinical presentation and demographics according to insurance status incompletely explain the variation in therapy. Further study is needed to validate and address these disparities and to evaluate the impact of health insurance legislative efforts in localized breast cancer.

Thomas M. Churilla, MD, Brian Egleston, PhD, Joshua Meyer, MD, Yanqun Dong, MD, PhD, Penny Anderson, MD; Fox Chase Cancer Center

INTRODUCTION: Various studies have suggested disparities in breast cancer care due to inadequate health insurance coverage. The purpose of our study was to test for associations between patient insurance status and the presentation and local therapy patterns among a large, nationally representative cohort of patients with localized breast cancer.

METHODS: We queried the National Cancer Institute (NCI) Survival, Epidemiology, and End Results (SEER) database for breast cancer cases diagnosed from 2007–2011 in women aged 18–64 years, limited to ductal or lobular histology, nonmetastatic stage, and treated with mastectomy or lumpectomy. Patients ≥ 65 years were excluded based on their eligibility for Medicare. We characterized clinical and demographic variables according to insurance status (insured vs Medicaid vs uninsured). We tested for associations between patient insurance status and choice of definitive surgical procedure (mastectomy vs breast-conserving surgery), omission of radiation therapy (RT) following breast-conserving surgery, and administration of postmastectomy RT (PMRT). We calculated odds ratios (ORs), performed Pearson’s chi-square test for univariable analysis, and used multiple logistic regression analysis to adjust for clinical and demographic covariates.

RESULTS: A total of 129,565 patients with localized breast cancer were analyzed. The health insurance statuses included insured (84.5%), Medicaid (11.5%), uninsured (2.1%), and unknown (1.9%). Patients with Medicaid or uninsured status were more likely to present with large, node-positive tumors and be black or unmarried and reside in low-income counties. The breast-conserving surgery rate was 51.3% among all patients and varied according to insurance status: insured (52.2%), uninsured (47.7%), and Medicaid (45.2%) (P < .001). Medicaid insurance status remained significantly associated with receipt of mastectomy in the multivariable analysis (OR =1.07; 95% confidence interval [CI], 1.03–1.11; P < .001). Radiation therapy was more frequently omitted after breast-conserving surgery in both Medicaid (OR = 1.14; 95% CI, 1.07–1.21) and uninsured (OR = 1.29; 95% CI, 1.14–1.47) patients in the multivariable analysis (P < .001 for both). PMRT was more frequently administered among Medicaid and uninsured patients; however, only Medicaid status remained significantly associated with PMRT in the multivariable analysis (OR = 1.10; 95% CI, 1.04–1.18; P = .002).

CONCLUSION: Patients with inadequate health insurance were more likely to receive mastectomy, omit RT following breast-conserving surgery, and receive PMRT. Differences in clinical presentation and demographics according to insurance status incompletely explain the variation in therapy. Further study is needed to validate and address these disparities and to evaluate the impact of health insurance legislative efforts in localized breast cancer.

Proceedings of the 97th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content